Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

BACKGROUND: Adults with certain medical and behavioral factors are at increased risk for pneumococcal disease (PD). Sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-risk adults in som...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammitt, Laura L, Quinn, Dean, Janczewska, Ewa, Pasquel, Francisco J, Tytus, Richard, Rajender Reddy, K, Abarca, Katia, Khaertynova, Ilsiyar M, Dagan, Ron, McCauley, Jennifer, Cheon, Kyeongmi, Pedley, Alison, Sterling, Tina, Tamms, Gretchen, Musey, Luwy, Buchwald, Ulrike K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826015/
https://www.ncbi.nlm.nih.gov/pubmed/35146039
http://dx.doi.org/10.1093/ofid/ofab605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826015/
https://www.ncbi.nlm.nih.gov/pubmed/35146039
http://dx.doi.org/10.1093/ofid/ofab605

Ejemplares similares